The relationship between HER2 status acquired from pathological data and metabolic parameters from pre-treatment [18F]FDG PET/CT in gastric adenocarcinomas Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos


Acar Tayyar M., ÖNER TAMAM M., Babacan G., ŞAHİN M., Özçevik H., Şengiz Erhan S., ...Daha Fazla

Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.44, sa.4, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 4
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.remn.2024.500080
  • Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
  • Anahtar Kelimeler: Gastric cancer, [F-18]FDG PET/CT, Metabolic parameters, HER2, Survival
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [18F]FDG PET/CT and to investigate its impact on survival. Methods: Pretreatment metabolic parameters measured by [18F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated. Results: Among the 117 patients, 17.1% were HER2-positive (HER2+), and 82.9% were HER2-negative (HER2−). There was no significant association between PET/CT parameters in the HER2+ and HER2− patient groups. HER2+ patients had higher 1- and 3-year survival expectations than HER2− patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG. Conclusion: This study showed no association between HER2 expression and [18F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.